Explore

Rapid ReadRapid Read
Stratified Medicine Advances in Oncology with Focus on Rare Cancers and Drug Repurposing

Stratified Medicine Advances in Oncology with Focus on Rare Cancers and Drug Repurposing

Stratified medicine, also known as precision medicine, is evolving to tailor disease prevention, diagnosis, and treatment based on an individual's genetic, protein, environmental, and lifestyle information. In oncology, a tumor budding-based grading system, proposed by the International Association for the Study of Lung Cancer (IASLC), is being utilized to stratify risk in patients with resected lung squamous cell carcinoma (SqCC). This system helps identify individuals who may benefit from adjuvant chemotherapy. Furthermore, recent advancements in precision oncology are enabling tumor-agnostic repurposing methods. These methods are crucial for identifying new therapeutic opportunities, particularly for rare and ultra-rare cancers, where traditional treatment options are often limited or non-existent. The approach involves leveraging existing genomic data from routine clinical care to find new uses for established drugs, moving beyond conventional 'on-target' approaches to explore 'off-target' vulnerabilit...
TrendlineTrendline
Biohacking Market Projected to Reach $131.5 Billion by 2035 Amidst Rising Demand for Preventive Healthcare

Biohacking Market Projected to Reach $131.5 Billion by 2035 Amidst Rising Demand for Preventive Healthcare

Biohacking Market Projected to Reach $131.5 Billion by 2035 Amidst Rising Demand for Preventive Healthcare
TrendlineTrendline
WilmerHale Advises Thermo Fisher Scientific in Biomedical Data Venture with Mayo Clinic

WilmerHale Advises Thermo Fisher Scientific in Biomedical Data Venture with Mayo Clinic

WilmerHale Advises Thermo Fisher Scientific in Biomedical Data Venture with Mayo Clinic
Rapid ReadRapid Read
AI System Accurately Reads Doctors' Written Notes, Unlocking Vast Medical Data for Research

AI System Accurately Reads Doctors' Written Notes, Unlocking Vast Medical Data for Research

Researchers from RespondHealth, Drexel University, Stanford University, the University of Miami, the University of Pennsylvania, and the Icahn School of Medicine at Mount Sinai have developed an AI system capable of accurately reading and analyzing doctors' handwritten clinical notes at scale. Published in Nature Medicine, this system converts narrative text into computable data, linking every extracted fact back to its original sentence. This innovation addresses a long-standing challenge in medical research, as a significant portion of patient information, including crucial details about patient coping mechanisms, side effects, and medication changes, resides in these previously inaccessible written notes. The system achieved a 99.4% accuracy rate in a combined measure of correctness and completeness when compared against an adjudicated standard set by board-certified physicians. This level of accuracy is particularly noteworthy given that physicians themselves agreed on 94.7% of statements they reviewed...
Rapid ReadRapid Read
Mobile Healthcare Market Projected to Reach $222.32 Billion by 2030 Amidst Digital Health Expansion

Mobile Healthcare Market Projected to Reach $222.32 Billion by 2030 Amidst Digital Health Expansion

The mobile healthcare market is experiencing significant expansion, with projections indicating a rise from $101.27 billion in 2025 to an estimated $222.32 billion by 2030. This growth is driven by several factors, including the proliferation of digital health initiatives, an increase in chronic disease rates, widespread smartphone usage, and the growing adoption of wearable health devices. Telemedicine services have also played a crucial role in this expansion, enabling real-time consultations and remote monitoring. Key trends shaping this outlook include the adoption of remote patient monitoring technologies, the rise of mobile diagnostic tools, greater integration of wearables, and enhanced real-time health data analytics. The market is segmented by device type, service type, and stakeholder, encompassing a wide range of products and services from blood glucose monitors to wellness and fitness solutions.
Rapid ReadRapid Read
Cigna Expands AI Integration to Combat Rising Healthcare Costs and Improve Patient Outcomes

Cigna Expands AI Integration to Combat Rising Healthcare Costs and Improve Patient Outcomes

Cigna Group is significantly increasing its use of artificial intelligence to address the escalating costs within the healthcare industry. The company is leveraging AI-driven insights combined with clinical expertise to identify emerging health needs earlier and guide members toward appropriate care. This strategic integration aims to prevent conditions from worsening, thereby reducing the need for more expensive interventions. Cigna's expanded AI-enabled care coordination capabilities are designed to detect conditions such as cancer, heart disease, and high-risk pregnancies at an earlier stage. The company anticipates that these enhanced capabilities will reach 20% more customers with complex health needs. Furthermore, Cigna is implementing AI in its specialty pharmacy division through the Pharmacy Forward program, which seeks to expedite the time between prescription and treatment and decrease administrative burdens for clinicians. This initiative is projected to halve the average time to therapy and red...
Rapid ReadRapid Read
Uterine Cancer Incidence and Mortality Rise, Exposing Deep Racial Disparities in the U.S.

Uterine Cancer Incidence and Mortality Rise, Exposing Deep Racial Disparities in the U.S.

Uterine cancer incidence and mortality are on the rise in the United States, making it the leading cause of death among gynecologic cancers, projected to surpass ovarian cancer in 2026. Despite overall declines in cancer mortality due to advances in prevention and treatment, uterine cancer stands as a notable exception. Elizabeth M. Swisher, MD, Chair of the AACR Cancer Prevention Working Group steering committee, highlights significant racial disparities, with Black women more likely to die from uterine cancer despite a lower overall incidence. This increased mortality among Black women is primarily driven by a higher prevalence of aggressive histologic subtypes, such as uterine serous carcinoma, carcinosarcoma, and clear cell carcinoma, which have higher mortality rates than other types. Swisher suggests that a combination of biological, economic, healthcare-related, and environmental factors contribute to these disparities, noting that Caribbean-born Black women have a lower risk of endometrial cancer t...
Rapid ReadRapid Read
University of Texas MD Anderson Cancer Center Identifies B Cells as Key in Immunotherapy-Related Colitis

University of Texas MD Anderson Cancer Center Identifies B Cells as Key in Immunotherapy-Related Colitis

Researchers at The University of Texas MD Anderson Cancer Center have uncovered a significant role for B cells in the development and persistence of colitis, a severe side effect of immune checkpoint inhibitors used in cancer treatment. The study, published in Cell Reports, was led by Roza Nurieva, Ph.D., professor of Immunology. The findings indicate that changes in circulating B cell activity can occur before patients experience any symptoms, suggesting B cells could serve as a predictive biomarker for the risk of immunotherapy-related colitis. Immune checkpoint inhibitors have revolutionized cancer treatment by enhancing the immune system's ability to fight cancer, but they can also trigger severe immune-related adverse events, including colitis, which causes inflammation of the colon, severe diarrhea, abdominal pain, and intestinal bleeding. The study found that higher levels of B cells before treatment were associated with an increased risk of colitis, and preclinical models showed that B cell activat...
Rapid ReadRapid Read
Oncogenomics Revolutionizes Cancer Treatment Decisions Through Genomic Analysis

Oncogenomics Revolutionizes Cancer Treatment Decisions Through Genomic Analysis

Oncogenomics is a specialized field focused on the genomic analysis of tumors to guide cancer treatment decisions. This approach involves studying mutations in oncogenes and tumor suppressor genes, which are critical in the transformation of healthy cells into malignant ones. By understanding these genetic alterations, oncogenomics plays a pivotal role in personalized medicine, allowing for treatments to be tailored to an individual's unique genetic profile. This customization aims to reduce adverse reactions and improve overall healthcare outcomes. The open-access journal Oncotarget actively publishes research across all aspects of oncology, highlighting the ongoing advancements and importance of this field in medical research and practice. Personalized medicine, which includes oncogenomics, has been gaining momentum since the Human Genome Project's completion in 2003, enabling rapid advancements in genetic testing to identify disease-associated mutations.
Rapid ReadRapid Read
OU Health Campus Explores AI's Potential to Revolutionize Healthcare in Oklahoma

OU Health Campus Explores AI's Potential to Revolutionize Healthcare in Oklahoma

The OU Health Campus recently hosted its first AI Symposium, bringing together leaders from the university and clinical enterprise to discuss the integration of artificial intelligence into healthcare, research, and education. The symposium focused on both the opportunities and risks associated with AI, particularly in the context of improving health outcomes in Oklahoma. Carlos Bustamante, Ph.D., vice dean of research at the OU College of Medicine, highlighted Oklahoma's unique position to leverage AI due to its significant health challenges, including high rates of diabetes, cancer, and cardiovascular conditions. AI is already being utilized for tasks such as triaging medical images and assisting clinicians with documentation, and it shows promise in predicting patient risk and hospital readmission rates. Ian Dunn, M.D., executive dean of the OU College of Medicine, emphasized the need to embrace AI while acknowledging its risks, noting that patients are increasingly using AI tools to research their own ...
Rapid ReadRapid Read
Memorial Sloan Kettering Cancer Center and OpenEvidence Partner to Integrate Precision Oncology Data into EHRs

Memorial Sloan Kettering Cancer Center and OpenEvidence Partner to Integrate Precision Oncology Data into EHRs

Memorial Sloan Kettering Cancer Center (MSK) and OpenEvidence have announced a partnership to advance precision oncology by integrating MSK's OncoKB™ knowledge base into OpenEvidence. This collaboration aims to provide clinicians nationwide with expert interpretation of cancer genomics directly within electronic health records (EHRs). OncoKB™, which is partially recognized by the U.S. Food and Drug Administration (FDA), offers evidence-based assertions on genetic alterations in cancer that can guide treatment decisions. The integration will allow OncoKB's curated content, including oncogenic effects, levels of evidence, and associated therapies, to be surfaced within OpenEvidence and Epic EHRs, alongside patient context. This initiative seeks to translate complex genomic reports into clear, evidence-based treatment paths, making MSK's expertise accessible to a broader network of cancer care providers across the U.S. More than half of U.S. hematologist-oncologists currently use OpenEvidence for complex onco...
TrendlineTrendline
Cell and Gene Therapy Industry Faces Scale-Up Challenges, Lifecycle Approach Proposed

Cell and Gene Therapy Industry Faces Scale-Up Challenges, Lifecycle Approach Proposed

Cell and Gene Therapy Industry Faces Scale-Up Challenges, Lifecycle Approach Proposed